Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder

Stefano Luzzago^{1

2}, Carlotta Palumbo^{3

4}, Giuseppe Rosiello^{3

5}, Angela Pecoraro^{3

6}, Marina Deuker^{3

7}, Francesco Alessandro Mistretta^{3

8}, Zhe Tian³, Gennaro Musi⁸, Emanuele Montanari⁹, Shahrokh F Shariat^{10

11

12

13

14}, Fred Saad³, Alberto Briganti⁵, Ottavio de Cobelli^{8

15}, Pierre I Karakiewicz³

Affiliations

¹ Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. stefanoluzzago@gmail.com.
² Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy. stefanoluzzago@gmail.com.
³ Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
⁴ Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
⁵ Division of Experimental Oncology, Department of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁶ Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.
⁷ Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
⁸ Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.
⁹ Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
¹⁰ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
¹¹ Department of Urology, Weill Cornell Medical College, New York, NY, USA.
¹² Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
¹³ Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
¹⁴ Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
¹⁵ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

PMID: 31960108
DOI: 10.1007/s00345-020-03083-5

Comparative Study

Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder

Stefano Luzzago et al. World J Urol. 2020 Nov.

. 2020 Nov;38(11):2819-2826.

doi: 10.1007/s00345-020-03083-5. Epub 2020 Jan 20.

Authors

Affiliations

¹ Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. stefanoluzzago@gmail.com.
² Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy. stefanoluzzago@gmail.com.
³ Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
⁴ Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
⁵ Division of Experimental Oncology, Department of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁶ Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.
⁷ Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
⁸ Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.
⁹ Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
¹⁰ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
¹¹ Department of Urology, Weill Cornell Medical College, New York, NY, USA.
¹² Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
¹³ Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
¹⁴ Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
¹⁵ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

PMID: 31960108
DOI: 10.1007/s00345-020-03083-5

Abstract

Purpose: To test the effect of tumor location (urachal vs. non-urachal) on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB).

Materials and methods: Within the Surveillance, Epidemiology, and End Results registry (2004-2016), we identified patients with non-metastatic (≤ T4N0M0) ADKUB. Stratification was made according to tumor location: urachal vs. non-urachal ADKUB. Kaplan-Meier plots and multivariable Cox regression models were fitted before and after 1:3 propensity score (PS) matching and separate Cox regression models were refitted before and after inverse probability of treatment weighting (IPTW).

Results: Of 1681 patients, 226 (13.5%) vs. 1455 (86.5%) harboured urachal vs. non-urachal ADKUB, respectively. Five-year cancer-specific survival (CSS) rates were, respectively, 75 vs. 67% for urachal vs. non-urachal ADKUB (p = 0.001). In subgroup analyses of ≤ T2N0M0 patients, 5-year CSS rates were, respectively, 84 vs. 73% for urachal vs. non-urachal ADKUB (p = 0.006). In subgroup analyses of T3-4N0M0 patients, 5-year CSS rates were, respectively, 68 vs. 49% for urachal vs. non-urachal ADKUB (p < 0.001). In multivariable Cox regression models, urachal ADKUB was associated with lower CSM rates (HR 0.6; p = 0.01). Virtually, the same findings were recorded after 1:3 PS matching (HR 0.6; p = 0.009) as well as when Cox regression models were refitted after IPTW (HR 0.7; p = 0.01).

Conclusion: The distinction between urachal vs. non-urachal ADKUB indicates better prognosis when the origin of the tumor is urachal, regardless of methodological approach used for the comparison.

Keywords: Adenocarcinoma; Inverse probability of treatment weighting; Non-urachal; Propensity score; Urachal.

PubMed Disclaimer

Comment in

Einfluss der Tumorlokalisation auf die Prognose von Blasentumoren.
[No authors listed] [No authors listed] Aktuelle Urol. 2022 Apr;53(2):116. doi: 10.1055/a-1324-0035. Epub 2022 Mar 28. Aktuelle Urol. 2022. PMID: 35345005 German. No abstract available.

References

1. Moschini M, D’Andrea D, Korn S et al (2017) Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 14:651 - DOI
1. Baumeister P, Zamboni S, Mattei A et al (2019) Histological variants in non-muscle invasive bladder cancer. Transl Androl Urol 8:34–38. https://doi.org/10.21037/tau.2019.01.09 - DOI - PubMed - PMC
1. Manunta A, Vincendeau S, Kiriakou G et al (2005) Non-transitional cell bladder carcinomas. BJU Int 95:497–502. https://doi.org/10.1111/j.1464-410X.2005.05327.x - DOI - PubMed - PMC
1. Szarvas T, Módos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma—a comprehensive review with meta-analysis of 1010 cases. Urol Oncol Semin Orig Investig 34:388–398. https://doi.org/10.1016/j.urolonc.2016.04.012 - DOI
1. Siefker-Radtke A (2006) Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther 6:1715–1721. https://doi.org/10.1586/14737140.6.12.1715 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder

Affiliations

Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder

Authors

Affiliations

Abstract

Comment in

References

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical